Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Explaining clinically important variability in response to simvastatin treatment using a PBPK/PD approach.

Journal of clinical pharmacology - 1 Feb 2026

Kang Wonho, Conchon Costa Ana Carolina, Medeiros Jose Ivan Marques, Cicali Brian, Salgado Junior Wilson, Schmidt Stephan, de Moraes Natalia Valadares

Abstract excerpt

Understanding exposure-response relationships is critical for the selection of an optimal drug dose that balances efficacy and safety. For simvastatin (SV), plasma concentrations may not accurately reflect target site exposure, because its pharmacologic effect is linked to intrahepatic unbound concentrations of its active form, simvastatin hydroxy acid (SVA). SVA is taken up into hepatocytes via the OATP1B1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Liver-Specific Organic Anion Transporter 1

Share to Obesity

Share to Simvastatin

Source

Identifiers

PMID: 41696832
DOI: 10.1002/jcph.70163

Genes

SLCO1B1
CYP3A4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Explaining clinically important variability in response to simvastatin treatment using a PBPK/PD approach.PMID 41696832Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.Semantic proximity Read ↗

Simvastatin therapy in different subtypes of hypercholesterolemia – a physiologically based modelling approachSemantic proximity Read ↗

Genomewide Association Study of Simvastatin Pharmacokinetics.Semantic proximity Read ↗

The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.Semantic proximity Read ↗

Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age-Related Studies in Thai Adults and Cross-Population Comparisons.Semantic proximity Read ↗

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.Semantic proximity Read ↗

Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.Semantic proximity Read ↗

Impacts of Pharmacokinetic Gene Polymorphisms on Steady-State Plasma Concentrations of Simvastatin in Thai Population.Semantic proximity Read ↗

Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients.Semantic proximity Read ↗

Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.Semantic proximity Read ↗

An update on efflux and uptake transporters as determinants of statin response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.